CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: CC-90009
Drug: Gilteritinib
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2020-04-07

Last Posted Date: 2024-05-31

Lead Sponsor: Celgene

Target Recruit Count: 22

Registration Number: NCT04336982

Locations: 🇺🇸
Local Institution - 104, San Francisco, California, United States
🇺🇸
Local Institution - 103, Boston, Massachusetts, United States
🇨🇦
Local Institution - 201, Toronto, Ontario, Canada

and more 11 locations

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Phase 1

Terminated

Conditions: Glioblastoma

Interventions: Drug: CC-90010
Drug: Temozolomide
Radiation: Radiotherapy

First Posted Date: 2020-03-27

Last Posted Date: 2024-07-26

Lead Sponsor: Celgene

Target Recruit Count: 184

Registration Number: NCT04324840

Locations: 🇳🇱
Local Institution - 400, Rotterdam, Netherlands
🇳🇴
Local Institution - 600, Oslo, Norway
🇳🇱
Local Institution - 408, Leiden, Zuid-Holland, Netherlands

and more 26 locations

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Enasidenib

First Posted Date: 2020-03-17

Last Posted Date: 2020-03-17

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT04310527

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: CC-90009
Radiation: [14C]

First Posted Date: 2020-03-05

Last Posted Date: 2021-12-17

Lead Sponsor: Celgene

Target Recruit Count: 8

Registration Number: NCT04297124

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: CC-99677
Drug: Methotrexate
Drug: Itraconazole
Drug: Midazolam
Drug: Sulfasalazine
Drug: Rifampin
Drug: Digoxin
Drug: Metformin
Drug: Rosuvastatin

First Posted Date: 2020-02-13

Last Posted Date: 2021-08-18

Lead Sponsor: Celgene

Target Recruit Count: 48

Registration Number: NCT04268394

Locations: 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2

Recruiting

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: JCAR017

First Posted Date: 2020-01-29

Last Posted Date: 2024-12-10

Lead Sponsor: Celgene

Target Recruit Count: 276

Registration Number: NCT04245839

Locations: 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Local Institution - 111, Santa Monica, California, United States
🇺🇸
University Of Colorado Cancer Center, Aurora, Colorado, United States

and more 54 locations

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Fedratinib
Drug: Digoxin
Drug: Rosuvastatin
Drug: Metformin

First Posted Date: 2020-01-18

Last Posted Date: 2020-05-21

Lead Sponsor: Celgene

Target Recruit Count: 24

Registration Number: NCT04231435

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Ozanimod

First Posted Date: 2019-12-26

Last Posted Date: 2021-03-25

Lead Sponsor: Celgene

Target Recruit Count: 24

Registration Number: NCT04211558

Locations: 🇨🇳
Capital Medical University - Beijing Anzhen Hospital, Beijing, China

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Rabeprazole
Drug: CC-92480

First Posted Date: 2019-12-26

Last Posted Date: 2020-05-08

Lead Sponsor: Celgene

Target Recruit Count: 24

Registration Number: NCT04211545

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: bb2121
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Lenalidomide

First Posted Date: 2019-12-12

Last Posted Date: 2023-08-23

Lead Sponsor: Celgene

Target Recruit Count: 13

Registration Number: NCT04196491

Locations: 🇺🇸
Local Institution - 117, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 108, Atlanta, Georgia, United States
🇺🇸
Local Institution - 110, Los Angeles, California, United States

and more 19 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy